MWM
LTRN icon

Meridian Wealth Management’s Lantern Pharma LTRN Stock Holding History

Meridian Wealth Management’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,945
Closed -$69.8K – 631
2024
Q2 		$69.8K Buy
+14,945
New +$89.9K 0.01% 283
2024
Q1 		– Sell
-19,660
Closed -$84.1K – 365
2023
Q4 		$84.1K Buy
19,660
+3,000
+18% +$10.6K 0.01% 582
2023
Q3 		$56.8K Buy
+16,660
New +$75.7K ﹤0.01% 531

Other funds holding LTRN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Meridian Wealth Management's LTRN Position: Q3 2024 in Review

Meridian Wealth Management sold out of Lantern Pharma (LTRN) in Q3 2024, closing a stake of 14,945 shares — an estimated $69.8K sold.

Meridian Wealth Management first reported a position in LTRN in Q3 2023 and held it in 3 quarters. The position peaked at $84.1K in Q4 2023. 31 funds tracked by Wall St. Rank hold LTRN as of Q3 2024.

  • Meridian Wealth Management reported no remaining Lantern Pharma position as of Q3 2024 after selling out during the quarter.
  • Meridian Wealth Management sold 14,945 Lantern Pharma shares in Q3 2024, an estimated $69.8K.
  • Meridian Wealth Management first reported a position in Lantern Pharma in Q3 2023 and held it in 3 quarters.
  • Meridian Wealth Management's Lantern Pharma position peaked at $84.1K in Q4 2023.
  • 31 funds tracked by Wall St. Rank held Lantern Pharma as of Q3 2024.

Based on Meridian Wealth Management's 13F filing for Q3 2024, filed 12 Nov 2024.